CD74 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1163667	1.00	15/20
SCHEMBL1988915	1.00	15/20
SCHEMBL2980660	0.60	10/20
SCHEMBL2973696	0.57	10/20
SCHEMBL2975020	0.58	9/20
SCHEMBL2978007	0.58	9/20
SCHEMBL2975010	0.56	9/20
SCHEMBL1163592	0.73	8/20
SCHEMBL2972028	0.54	8/20
SCHEMBL2980425	0.52	8/20
SCHEMBL2967059	0.65	7/20
SCHEMBL1163858	0.63	7/20
SCHEMBL2973793	0.61	7/20
SCHEMBL2757854	0.58	7/20
SCHEMBL2979225	0.58	7/20
SCHEMBL2971886	0.57	7/20
SCHEMBL2969879	0.56	7/20
SCHEMBL2977635	0.55	7/20
SCHEMBL2975035	0.54	7/20
SCHEMBL1163905	0.54	7/20

Clinical trials — most relevant to CD74 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis	PHASE4	COMPLETED
Belatacept 3 Month Post Transplant Conversion Study	PHASE4	COMPLETED
Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT	PHASE1/PHASE2	COMPLETED
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders	PHASE2	COMPLETED
CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection	PHASE1/PHASE2	RECRUITING
The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2	PHASE2	NOT_YET_RECRUITING
Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma	PHASE2	COMPLETED
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers	PHASE1/PHASE2	RECRUITING
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Autologous Dendritic Cell Vaccine for Treatment of Patients With Chronic HCV-Infection	PHASE1/PHASE2	COMPLETED
CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk	PHASE1/PHASE2	RECRUITING
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma	PHASE1/PHASE2	COMPLETED
Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple Myeloma	PHASE2	COMPLETED
GVAX in Advanced Prostate Cancer Patients Made Lymphopenic	PHASE1/PHASE2	UNKNOWN
RBL001/RBL002 Phase I Clinical Trial	PHASE1	COMPLETED
Dose Escalation Study of Immunomodulatory Nanoparticles	PHASE1	ACTIVE_NOT_RECRUITING
Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults	PHASE1	COMPLETED
Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc	PHASE1	COMPLETED
The Role of Circulating Soluble CD74 in Acute Lung Injury	nan	COMPLETED
TIGIT in Patients With Chronic Myeloid Leukemia	nan	UNKNOWN
Genetic Analysis of Psoriasis and Psoriatic Arthritis	nan	COMPLETED
Th1/Th2/Th17/TREG and TLRs Activation/KIR for COVID 19 Prediction of Outcome	nan	COMPLETED
Individualizing Anti-TNF Therapy in Patients With Inflammatory Bowel Disease	nan	RECRUITING
Different Susceptibility to SARS CoV-2 Infection Among Health Care Workers Highly Exposed to COVID-19.	nan	COMPLETED
KIR Genes and Non-Celiac Wheat Sensitivity	nan	COMPLETED
Role of Neutrophil CD64 and Monocyte HLA-DR Markers in the Dignosis of Neonatal Sepsis	nan	UNKNOWN
Adding DNA-test for Screening of HLA-DQ2 and DQ8 to Improve Early Diagnosis of Celiac Disease	nan	UNKNOWN
Comparison of the Severity of Coronary Atherosclerosis With Tissue Compliance in Patients Within First Degree Relatives	nan	UNKNOWN
LANDscape MApping of Epitopes and T Cell Receptors for Selected Cancers	nan	RECRUITING
Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a CD74 binder may also engage these)

Protein	Name	Similarity
P10247	—	0.998	P10247 →
P04441	—	0.998	P04441 →
Q9D9J7	—	0.983	Q9D9J7 →
Q9Z136	—	0.981	Q9Z136 →
Q640L3	—	0.981	Q640L3 →
Q9CZN4	—	0.981	Q9CZN4 →
Q8QHJ9	—	0.981	Q8QHJ9 →
Q6AY06	—	0.981	Q6AY06 →
Q155Q3	—	0.981	Q155Q3 →
P58821	—	0.980	P58821 →
Q8NEA5	—	0.980	Q8NEA5 →
Q96ST8	—	0.980	Q96ST8 →
Q06335	—	0.980	Q06335 →
A2AHC3	—	0.980	A2AHC3 →
Q61137	—	0.980	Q61137 →
Q8BHP7	—	0.979	Q8BHP7 →
Q8HYZ0	—	0.979	Q8HYZ0 →
Q701R2	—	0.979	Q701R2 →
O88480	—	0.979	O88480 →
Q5F3A4	—	0.979	Q5F3A4 →
Q2M243	—	0.979	Q2M243 →
Q90VY2	—	0.979	Q90VY2 →
B3DHW5	—	0.978	B3DHW5 →
D4AEC2	—	0.978	D4AEC2 →
Q9EP53	—	0.978	Q9EP53 →
Q91XN4	—	0.978	Q91XN4 →
Q9QY73	—	0.978	Q9QY73 →
Q8N4X5	—	0.978	Q8N4X5 →
P35054	—	0.978	P35054 →
Q8VDP4	—	0.978	Q8VDP4 →